Search Results
Your search for The ASCO ,The ASCO matches 21475 pages
Showing 20601 - 20650FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome–negative, relapsed or refractory precursor B-cell acute lymphoblastic leukemia (B-cell ALL). Blinatumomab is a bispecific...
RSNA Awards Gold Medal to Three Leaders in Radiology
The Radiological Society of North America (RSNA) awarded the Gold Medal, the organization’s highest honor, to three individuals at the RSNA 100th Scientific Assembly and Annual Meeting: Gary J. Becker, MD, of Tucson; Allen S. Lichter, MD, FASCO, of Alexandria, Virginia; and Etta D. Pisano,...
Risk-Based Screening Misses Over 75% of Invasive Breast Cancers in Women in Their 40s
A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer. Results of the study were presented today at RSNA 2014, the annual meeting of the...
3D Mammography Improves Cancer Detection in Dense Breasts
A new study presented at RSNA 2014, the annual meeting of the Radiological Society of North America, has found that digital breast tomosynthesis, also known as three-dimensional (3D) mammography, has the potential to significantly increase the cancer detection rate in mammography screening of women ...
Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib as a first-line treatment in combination with paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Necuparanib is a novel oncology drug candidate engineered from...
FDA Grants Breakthrough Therapy Designation to Investigational CAR T-Cell Therapy
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to JCAR015, an investigational chimeric antigen receptor therapy developed by Juno Therapeutics. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and was filed...
FDA Warns Against Using Laparoscopic Power Morcellators to Treat Uterine Fibroids
The U.S. Food and Drug Administration (FDA) today announced that it is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids. In an updated safety communication, originally issued in April 2014, the FDA warned against using...
Adult Survivors of Retinoblastoma Experience Few Cognitive or Social Setbacks
Adult survivors of retinoblastoma, a type of eye cancer that usually develops in early childhood, have few cognitive or social problems decades following their diagnosis and treatment, according to a study by Brinkman et al published in Cancer. The findings offer good news for patients, but the...
High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pretreated With VEGF-Targeted Therapies
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pretreated with VEGF-targeted agents, according to research presented recently at the ESMO Symposium on Immuno-Oncology in Geneva (Abstract 4O). “Despite the wide and increasing range of therapies...
Immune Checkpoint Inhibitors May Work in Brain Cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...
FDA Approves Extended-Release, Single-Entity Hydrocodone Product With Abuse-Deterrent Properties
The U.S. Food and Drug Administration (FDA) today approved hydrocodone bitartrate (Hysingla ER), an extended-release opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The product...
Researchers Identify Biomarker of Response to New Ovarian Cancer Drug
Researchers have found a way to identify which ovarian cancer patients are likely to respond well to a new anticancer drug called rucaparib. Previous clinical trials have shown that women with platinum-sensitive tumors with BRCA1/2 mutations respond well to rucaparib. In new findings presented...
Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer
Results from the ARMOR2 of the anticancer drug galeterone shows that it is successful in lowering prostate-specific antigen (PSA) levels in men with a variant form castration-resistant prostate cancer. The findings, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...
IDH1 Inhibitor Demonstrates Anticancer Activity in Advanced Leukemia
A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation. The...
FDA Grants Orphan Drug Designation to BGB324 for Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BGB324 for the treatment of acute myeloid leukemia (AML). BGB324 is a first-in-class, highly selective small-molecule inhibitor of the Axl receptor tyrosine kinase. It blocks the epithelial-mesenchymal transition...
Metabolic ‘Reprogramming’ by the p53 Gene Family Leads to Tumor Regression
Scientists have found that altering members of the p53 gene family, known as tumor-suppressor genes, causes rapid regression of tumors that are deficient in or totally missing p53. Study results suggest existing diabetes drugs, which impact the same gene-protein pathway, might be effective for...
ASCO Calls for Major Medicaid Reform to Improve Quality Cancer Care for Low-Income Americans
ASCO issued its new Policy Statement on Medicaid Reform yesterday, which calls for major changes to the program to ensure access to high-quality cancer care for all low-income individuals. The Society’s recommendations call for Medicaid expansion in all 50 states to close coverage gaps,...
FDA Approves Bevacizumab Plus Chemotherapy for Platinum-Resistant, Recurrent Ovarian Cancer
The U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. AURELIA Trial ...
Gene Sequencing Projects Link Two Mutations to Ewing Sarcoma Subtype With Poor Prognosis
An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma and that define a subtype of the cancer associated with reduced survival. The research, conducted by the St. Jude Children’s Research Hospital-Washington University...
HPV Vaccine Uptake Among Girls Is Lowest in States With Highest Rates of Cervical Cancer
The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health...
Even With Equal Health-Care Access, Cancer Survival Rates Are Worse in American Indians and Alaskan Natives
The 5- and 10-year cancer survival rates were lower among American Indians and Alaskan Natives compared with non-Hispanic whites even when they had approximately equal access to health care, according to data presented at the American Association for Cancer Research (AACR) conference on The Science ...
CMS Announces Proposed Decision to Cover Low-Dose CT Screening for Lung Cancer
The Centers for Medicare & Medicaid Services (CMS) announced today that there is sufficient evidence to cover lung cancer screening with low-dose computed tomography (CT) screening for individuals at high risk for lung cancer. Earlier this year, the U.S. Preventive Services Task Force...
Video-Assisted Thoracoscopic Surgery Technique for Pneumonectomy Shown to Be Safe
In the largest series of its kind to date, researchers at Roswell Park Cancer Institute (RPCI) have shown that performing thoracoscopic pneumonectomy, removal of the entire lung through a minimally invasive endoscopic approach, at a high-volume center appears to be safe and may provide pain and...
Olaparib Treatment Yields Promising Response Rates in Patients With BRCA Mutation–Associated Cancers
Olaparib, an experimental twice-daily oral cancer drug, produced an overall tumor response rate of 26% in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to a phase II study reported by Kaufman et al in the Journal of Clinical Oncology. The positive response provides...
Number of Young Patients With Newly Diagnosed Colorectal Cancer Anticipated to Double
In the next 15 years, more than 1 in 10 colon cancers and nearly 1 in 4 rectal cancers will be diagnosed in patients younger than the traditional screening age, according to researchers at The University of Texas MD Anderson Cancer Center. This growing public health problem is underscored by data...
Study Shows Integrative Medicine Can Relieve Pain and Anxiety for Cancer Inpatients
Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health-care providers. The Penny George Institute for Health and Healing researchers found that integrative medicine therapies can substantially decrease pain and...
CDC Reports That Millions of U.S. Women Are Not Getting Screened for Cervical Cancer
Despite evidence that cervical cancer screening saves lives, about 8 million women aged 21 to 65 years have not been screened for cervical cancer in the past 5 years, according to a new report from the Centers for Disease Control and Prevention (CDC) published in Morbidity and Mortality Weekly ...
FDA Approves Ramucirumab in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The U.S. Food and Drug Administration (FDA) today approved ramucirumab (Cyramza) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ramucirumab was approved in April 2014 as a single agent for the treatment of...
New Guidelines Issued on Use of Complementary Therapies for Breast Cancer
More than 80% of breast cancer patients in the United States use complementary therapies following a breast cancer diagnosis, but there has been little science-based guidance to inform clinicians and patients about their safety and effectiveness. In newly published clinical practice guidelines...
ASCO Endorses AUA/ASTRO Guideline on Adjuvant and Salvage Radiotherapy After Prostatectomy
The American Society of Clinical Oncology (ASCO) today issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on the use of adjuvant and salvage radiotherapy after prostatectomy, which was based on a systematic review of medical...
Rewiring Cell Metabolism Slows Colorectal Cancer Growth
Cancer is an unwanted experiment in progress. As the disease advances, tumor cells accumulate mutations, eventually arriving at ones that give them the insidious power to grow uncontrollably and spread. Distinguishing drivers of cancer from benign mutations open opportunities for developing...
Registry Data Reveals Sustained Local Control With Minimal Side Effects for Medically Inoperable, Early-Stage Lung Cancer Patients Receiving SBRT
Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control in 79% of tumors for medically inoperable, early-stage lung cancer patients treated with the procedure from 2003 to 2012, according to research presented at...
Postoperative Radiation Therapy Improves Overall Survival for Patients With Resected Pathologic N2 Non–Small Cell Lung Cancer
Patients who received postoperative radiation therapy lived an average of 4 months longer when compared to the patients who had the same disease site, tumor histology, and treatment criteria and who did not receive postoperative radiotherapy, according to research presented at the 2014 Chicago ...
Cancer Leaders Call for Congress to Act Quickly in 2015 to Reinvigorate Cancer Innovation in the United States
Even before the next Congress is formally elected, a national group of health-care stakeholders called the Cancer Innovation Coalition (CIC) went to Capitol Hill today to call for early legislative and regulatory action in 2015 that will reinvigorate cancer innovation in the United States. The...
Molecular Tumor Markers Could Reveal New Therapeutic Targets for Lung Cancer Treatment
Analysis of 607 small cell lung cancer (SCLC) tumors and neuroendocrine tumors identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented at the 2014 Chicago Multidisciplinary...
No Difference in Survival Rates in Patients With Lung Adenocarcinoma In Situ vs Minimally Invasive Adenocarcinoma
Lung cancer patients with minimally invasive adenocarcinoma have similar, positive 5-year disease-free survival and overall survival rates as patients with adenocarcinoma in situ, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology (Abstract...
Medicare Costs Analysis Indicates Need for Decreasing Use of Biopsies as Diagnosis Tool for Lung Cancer
Biopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology (Abstract 103). The study examined the utilization rates and estimated the Medicare costs of the lung...
Patients at High-Risk for Lung Cancer Are More Likely to Receive Screening When Primary Care Provider Is Familiar With Guideline Recommendations
Patients at high-risk for developing lung cancer are more likely to receive low-dose computed tomography (CT) screening when their primary care provider is familiar with guideline recommendations for low-dose CT screening for lung cancer, according to research presented today at the 2014 Chicago...
Oncology Advances Included in Cleveland Clinic's Top 10 Medical Innovations List for 2015
Antibody-drug conjugates, checkpoint inhibitors, and single-dose intraoperative radiation therapy for breast cancer were included in the Cleveland Clinic's Ninth Annual Top 10 Medical Innovations List released earlier today. The list identifies those advances likely to have a major impact on...
New Research Shows Association of Kidney Cancer With Use of Aristolochic Acid
New research by the international Cancer Genomics of the Kidney consortium (CAGEKID) reveals an important connection between kidney cancer and exposure to aristolochic acid, an ingredient in some herbal remedies. The findings, published by Scelo et al in Nature Communications, have important...
Chest Radiation to Treat Childhood Cancer Increases Patients’ Risk of Developing Breast Cancer
A new study has found that patients who received chest radiation for Wilms tumor, a rare childhood cancer, face an increased risk of developing breast cancer later in life due to their radiation exposure. Reported by Lange et al in Cancer, the findings suggest that cancer screening guidelines might ...
FDA Grants Breakthrough Therapy Designation Pembrolizumab in Advanced Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the anti–PD-1 therapy pembrolizumab (Keytruda) for the treatment of patients with epidermal growth factor receptor (EGFR) mutation–negative, and anaplastic lymphoma kinase (ALK)...
Genomic Sequencing More Efficient in Predicting Breast Cancer Risk Than Previously Thought
Using genomic sequencing data on all currently known genetic alterations in breast cancer, it is possible to identify a woman’s genetic risk for the disease, and this approach can bring greater gains in disease prevention than previously estimated, according to a study reported by Sieh et al...
Loss of Y Chromosome Associated With Higher Mortality and Risk of Cancer in Men
Age-related loss of the Y chromosome from blood cells, a frequent occurrence among elderly men, is associated with elevated risk of various cancers and earlier death, according to research presented at the American Society of Human Genetics 2014 Annual Meeting in San Diego (Abstract 295). This...
Many Insured Patients Alter Their Lifestyles and Medical Care to Cope With Cancer Treatment Costs
A small nationwide survey finds many insured patients are changing their lifestyle and medical care in the face of treatment-related financial burdens. In fact, more than one-third adopted medical care–altering strategies, with younger and lower-income patients being more likely to alter...
One-Third of U.S. Cancer Survivors May Be Experiencing Financial or Work-Related Hardship
New results from a survey of nearly 1,600 cancer survivors indicate a high prevalence of financial and work-related difficulties: 27% reported at least one financial problem (eg, debt, bankruptcy), and 37% reported having to modify work plans, such as taking extended time off or delaying...
‘Smart Technology’ System for Home Hospice Symptom Management and Care Helps Both Patients With Cancer and Family Caregivers
Early findings from a study of 319 families suggest that use of an innovative, telephone-based symptom monitoring and coaching system during home hospice care leads to significantly decreased patient symptoms in the final weeks of life. The findings will be presented at the 2014 Palliative Care in...
Partnership Between Medical Oncologists and Palliative Care Specialists Improves Outcomes at an Inpatient Oncology Unit
First evaluation of a pioneering “co-rounding” partnership between medical oncologists and palliative care specialists at Duke University Medical Center shows improvements in both health system–related and patient-related outcomes. The first year of the new partnership—set...
Blood Biomarker May Detect Lung Cancer
A new study shows that patients with stage I to III non–small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract was released today in an online supplement to the journal CHESTand will be...
